Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Vaxart, Inc.

Market Cap 136M 117M 108M 101M 190M 12.81B 192M 1.28B 497M 6.29B 509M 499M 21.75B P/E 2026 *
1.94x
P/E 2027 * -0.58x
Enterprise Value 136M 117M 108M 101M 190M 12.81B 192M 1.28B 497M 6.29B 509M 499M 21.75B EV / Sales 2026 *
0.38x
EV / Sales 2027 * -
Free-Float
98.36%
Yield 2026 *
-
Yield 2027 * -
1 day+2.09%
1 week-2.66%
Current month-10.96%
1 month-8.48%
3 months-14.92%
6 months+55.68%
Current year+65.79%
1 week 0.55
Extreme 0.55
0.6
1 month 0.55
Extreme 0.55
0.72
Current year 0.34
Extreme 0.3434
0.84
1 year 0.26
Extreme 0.2606
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
10.33
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 2024-03-17
Chief Tech/Sci/R&D Officer 59 2024-02-29
Director of Finance/CFO - 2025-05-18
Director TitleAgeSince
Director/Board Member 68 2021-04-20
Director/Board Member 76 2022-08-03
Director/Board Member 79 2021-03-31
Date Insider Type Main position Quantity % Market Cap.
05-21Buy

Director

10,000 0.0041%
05-18Tax

Chief Financial Officer

-31,395 0.0130%
04-22Free

Director

236,200 0.0982%
Change 5-day change 1-year change 3-year change Capi.($)
+0.53%-2.66%-3.59%-38.82% 136M
+3.23%+2.25%+65.02%+116.66% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+2.87%+6.91%-12.26%-16.23% 22.63B
+3.59%+7.27%-1.72%+387.68% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.87%+13.67%-38.00% 14.83B
+1.09%+0.41%+27.66%+178.75% 13.1B
-5.17%+4.13%+13.12% - 12.66B
+0.98%+7.15%+80.62%+105.73% 11.56B
Average +1.36%-0.14%+23.86%+77.27% 20.98B
Weighted average by Cap. +1.67%+0.18%+33.36%+91.49%

Financials

2026 *2027 *
Net sales 356M 307M 282M 266M 499M 33.59B 503M 3.35B 1.3B 16.48B 1.34B 1.31B 57.03B -
Net income 116M 100M 92.01M 86.6M 163M 10.95B 164M 1.09B 424M 5.37B 435M 426M 18.59B -284M -245M -225M -212M -398M -26.8B -402M -2.67B -1.04B -13.15B -1.07B -1.04B -45.51B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
26-06-17 0.5655 $ +0.53% 123,589
26-06-16 0.5625 $ -2.17% 735,469
26-06-15 0.5750 $ +2.69% 337,493
26-06-12 0.5600 $ -1.12% 290,762
26-06-11 0.5663 $ -4.02% 275,711
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5625USD
Average target price
3.000USD
Spread / Average Target
+433.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!